Search results
Results From The WOW.Com Content Network
We would like to show you a description here but the site won’t allow us.
Randomized Phase II Study of 2nd Line FOLFIRI versus Modified FOLFIRI with PARP Inhibitor ABT-888 (Veliparib) in Metastatic Pancreatic Cancer.